Jame Abraham, MD on A Phase I Open Label Study of SGN-LIV1A: Antibody Drug Conjugate #ASCO2020 @CleClinicMD @jamecancerdoc

Jame Abraham, MD on A Phase I Open Label Study of SGN-LIV1A: Antibody Drug Conjugate #ASCO2020 @CleClinicMD @jamecancerdoc

User Photo
Cancer-News

3 months
29 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year's virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Up Next Autoplay